Peter Facchini News Today

Presentations highlight research involving Enveric’s EVM301 Series of non-hallucinogenic neuroplastogens and the company’s lead product candidate, EB-373 ...

Paper co-authored by Enveric researchers describes the discovery of a key cane toad enzyme and its application to the biosynthesis of novel indolethylamine-type drug candidates with potential use in...

Research highlights the potential of Enveric’s EVM201 Series aimed at developing psilocin prodrugs with altered metabolic profiles that offer superior administration and treatment benefits, but... | May 22, 2023

We're following this survey throughout the day and into tomorrow. Tune in to News5 at 4 p.m. as we review the results.

​As schools prepare for the next year, many administrators are looking at their safety plans. Security consultants saw a lot of demand this summer and share what schools should be focusing on.

-- Advancing to IND-enabling studies with multiple drug candidates ---- Enveric’s Growing Patent Portfolio Validated --CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspire...

/PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience company developing next-generation, psychedelic-inspired mental...

/PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused pharmaceutical company developing next-generation,...

/PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused pharmaceutical company developing next-generation,...

The dream is a big one: making opioid painkillers that are less addictive and adapting opioids into other medicines such as antibiotics and cancer treatments.